SAGE Therapeutics, Inc. (NASDAQ:SAGE) Q3 2023 Earnings Conference Call November 7, 2022 8:00 AM ET
Company Participants
Ashley Kaplowitz - Director, IR
Barry Greene - President, CEO & Director
Christopher Benecchi - Chief Business Officer
Kimi Iguchi - CFO & Treasurer
Laura Gault - Chief Medical Officer
Conference Call Participants
Ritu Baral - TD Cowen
Anupam Rama - JPMorgan Chase & Co.
Tazeen Ahmad - Bank of America Merrill Lynch
Salveen Richter - Goldman Sachs Group
Jay Olson - Oppenheimer
Ami Fadia - Needham & Company
Paul Matteis - Stifel, Nicolaus & Company
George Farmer - Scotiabank
Sumant Kulkarni - Canaccord Genuity
Leonid Timashev - RBC Capital Markets
Laura Chico - Wedbush Securities
Operator
Good morning. Welcome to Sage Therapeutics' Third Quarter 2023 Conference Call. [Operator Instructions]. This call is being webcast live on the Investors and Media section of Sages' website at sagerx.com. This call is the property of Sage Therapeutics and recording, reproduction or transmission of this call without the express written consent of Sage Therapeutics is strictly prohibited. Please note this call is being recorded.
I would now like to introduce Ashley Kaplowitz, Director of Investor Relations at Sage.
Ashley Kaplowitz
Good morning and thank you for joining Sage Therapeutics' third quarter 2023 financial results conference call. Before we begin, I encourage everyone to go to the Investors and Media section of our website at sagerx.com where you can find the press release related to today's call as well as slides that we will be reviewing today.
I would like to point out that we will be making forward-looking statements which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please review the risk factors discussed in today's press release and our SEC filings for additional details.
We will begin the call with prepared remarks by Barry Greene, our Chief Executive Officer, who will provide an overview of our progress during the third quarter of 2023. Our Chief Business Officer Chris Benecchi will provide an update on our preparations for the planned commercial availability and launch of ZURZUVAE.
We will also be joined by Laura Gault, our Chief Medical Officer, who will review recent progress across our pipeline, and by Kimi Iguchi, our Chief Financial Officer who will review the financial results from the third quarter of 2023. Mike Quirk, our Chief Scientific Officer will be available for questions during the Q&A portion of the call.